Pulse Biosciences (NASDAQ:PLSE – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, RTT News reports. During the same period last year, the business posted ($0.19) earnings per share.
Pulse Biosciences Stock Performance
Shares of Pulse Biosciences stock traded down $1.80 during trading hours on Thursday, reaching $15.92. The company’s stock had a trading volume of 52,394 shares, compared to its average volume of 199,585. Pulse Biosciences has a one year low of $4.24 and a one year high of $22.69. The company’s 50 day simple moving average is $17.70 and its 200 day simple moving average is $14.22. The stock has a market cap of $975.74 million, a P/E ratio of -20.01 and a beta of 1.74.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Friday, September 20th.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
- Five stocks we like better than Pulse Biosciences
- What Are Dividends? Buy the Best Dividend Stocks
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Best Stocks Under $10.00
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
